Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

Teva (TEVA) is making the branded-drug pivot work, with its three key products growing sales 33% year-over-year to $1.1 billion in Q3. Austedo, Ajovy and Uzedy drove that gain, and gross margin improved to 55.5%.

The mix shift has not yet lifted the top line. Total Q3 revenue fell 2%, as generic drug competition continues to erode the legacy business. That gap, branded strength against generic drag, is the core tension in the story.

The balance sheet adds support. Teva has paid down $12 billion in debt since 2019 and has received investment-grade ratings, a meaningful change in credit profile for a company once defined by leverage concerns.

Valuation sits below 21x forward earnings. Interpretation: the multiple suggests the market still prices in the generic headwind rather than fully crediting the branded transition, though the source offers no price target or earnings estimate to confirm how much upside that implies.